Long-Term Favorable Outcome With Nivolumab in a Case of Advanced Non-Small Cell Lung Cancer: A Case Report

Non-small cell lung cancer (NSCLC) constitutes around 85% of lung cancer cases. Advanced non-small cell lung cancer has a poor prognosis. Immunotherapy plays a pivotal role in managing advanced non-small cell lung cancer not positive for driver mutations. Nivolumab is a monoclonal antibody against p...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Vijay Ketan, Shrestha, Dhan B, Gaire, Suman, Mir, Wasey Ali Yadullahi, Kassem, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575281/
https://www.ncbi.nlm.nih.gov/pubmed/34765329
http://dx.doi.org/10.7759/cureus.18526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575281/
https://www.ncbi.nlm.nih.gov/pubmed/34765329
http://dx.doi.org/10.7759/cureus.18526

Ejemplares similares